Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Liabilities (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Total Liabilities for 5 consecutive years, with $213.4 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 126.16% to $213.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $213.4 million through Dec 2025, up 126.16% year-over-year, with the annual reading at $213.4 million for FY2025, 126.16% up from the prior year.
  • Total Liabilities hit $213.4 million in Q4 2025 for ARS Pharmaceuticals, down from $225.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $225.1 million in Q3 2025 to a low of $2.4 million in Q4 2023.
  • Historically, Total Liabilities has averaged $46.4 million across 5 years, with a median of $15.9 million in 2022.
  • Biggest five-year swings in Total Liabilities: plummeted 80.47% in 2022 and later soared 3786.12% in 2024.
  • Year by year, Total Liabilities stood at $16.7 million in 2021, then crashed by 48.73% to $8.5 million in 2022, then plummeted by 71.6% to $2.4 million in 2023, then skyrocketed by 3786.12% to $94.4 million in 2024, then soared by 126.16% to $213.4 million in 2025.
  • Business Quant data shows Total Liabilities for SPRY at $213.4 million in Q4 2025, $225.1 million in Q3 2025, and $121.2 million in Q2 2025.